Our Research
Our laboratory utilizes the BH3 profiling technique to study the effects of novel agents such as B cell receptor inhibitors, Bcl-2 antagonists, and monoclonal antibodies on the mitochondria of CLL cells. We do ex vivo work on patient samples to devise novel combination strategies to explore in the clinic. We also study in vivo samples from patients already on clinical trials to assess the effects of these new drugs in patients.
Our ongoing clinical trials include:
For additional information on clinical trials, please contact the DFCI clinical trials office at 877-338-7425.
- A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO)
- A Phase I/II Study of Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL
- A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or CHOP-R for Patients With Richter's Syndrome
- A Phase 1b Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR)
- A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- A Phase 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation
- A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies
- A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies
- A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)
- A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring Chronic Lymphocytic Leukemia
- A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)
- A PHASE IB/II STUDY OF APG-2575 AS A SINGLE AGENT OR IN COMBINATION WITH OTHER THERAPEUTIC AGENTS IN PATIENTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (SACRED)
For additional information on clinical trials, please contact the DFCI clinical trials office at 877-338-7425.
Our laboratory studies that draw on samples from these trials utilize a technique developed by our close collaborators in the Letai Lab. The following articles provide an introduction to the BH3 profiling technique:
